UBS Group
VRXAW

UBS Group’s Veraxa Biotech AG Warrants VRXAW Stock Holding History

UBS Group’s Portfolio VRXAW Stock Details VRXAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+1
New – ﹤0.01% 11682

Other funds holding VRXAW

CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 27.56% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $7.65B AUM 13.87% 1-Year Est. Return

UBS Group's VRXAW Position: Q2 2026 in Review

UBS Group opened a new position in Veraxa Biotech AG Warrants (VRXAW) in Q2 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #11682 among its holdings.

26 funds tracked by Wall St. Rank hold VRXAW as of Q2 2026.

  • UBS Group held 1 share of Veraxa Biotech AG Warrants worth $0 as of Q2 2026.
  • Veraxa Biotech AG Warrants was a new UBS Group position in Q2 2026.
  • Veraxa Biotech AG Warrants made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #11682 holding.
  • 26 funds tracked by Wall St. Rank held Veraxa Biotech AG Warrants as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.